Answers are grounded in this paper and cite their sources.
Background Endoscopic remission (ER) is a key therapeutic goal in Crohn’s disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear.Methods We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn’s Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment.Results Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32–0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39–1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24–0.78, p = 0.005).Conclusions Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: